Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.wiley.com/authorresources/onlineopen.html
1538-7836/asset/olbannerleft.gif?v=1&s=77e14c4c55f90ae6eb6fec99ac201108f7c92510)
1538-7836/asset/olbannerright.gif?v=1&s=87cd273ca1fd9dc5d95b1da3d90fa3ee7637f329)
You have full text access to this OnlineOpen article
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
Article first published online: 29 MAR 2010
DOI: 10.1111/j.1538-7836.2010.03757.x
© 2010 International Society on Thrombosis and Haemostasis
Additional Information
How to Cite
BJÖRKMAN, S., BLANCHETTE, V. S., FISCHER, K., OH, M., SPOTTS, G., SCHROTH, P., FRITSCH, S., PATRONE, L., EWENSTEIN, B. M., FOR THE ADVATE CLINICAL PROGRAM GROUP and COLLINS, P. W. (2010), Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 8: 730–736. doi: 10.1111/j.1538-7836.2010.03757.x
Publication History
- Issue published online: 29 MAR 2010
- Article first published online: 29 MAR 2010
- Received 24 September 2009, accepted 8 January 2010
References
- 1. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77(Suppl): 5–99.
- 2, , , . Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25–32.
- 3, , , , , , , , , , rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413–20.
- 4, , , , , , , . Individualizing of factor VIII dosage. J Clin Hosp Pharm 1984; 9: 95–103.
- 5, , , , . Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365–80.
- 6, , , . Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247–52.
- 7, . The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1–8.Direct Link:
- 8, , , , . Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96–101.Direct Link:
- 9, . Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815–32.
- 10. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl. 1): 101–10.
- 11, , . Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571–82.
- 12, , , , , , , . Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985; 34: 22–8.
- 13, , , , , , , . Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494–8.
- 14, , , , , , , . Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability. Haemophilia 2006; 12: 40–9.
- 15, , , , , , , , for the rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319–26.
- 16, , . Pharmacokinetics and dose requirements of factor VIII over the age range of 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989–98.
- 17, , , . Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol 1982; 35: 289–91.
- 18, , , . Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385–95.
- 19, , . The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384–6.
- 20. Comparative pharmacokinetic studies in haemophilia. Haemophilia 2002; 8(Suppl. 2): 30–3.
- 21, , , . The pharmacokinetics of coagulation factors. Haemophilia 2006; 12(Suppl. 3): 1–7.
- 22, , , and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. http://www.isth.org/Publications/OfficialCommunications/Factor8and9/Pharmacokinetic.aspx. Accessed 24 July 2009.
- 23, , , , , , , , , , , , , the RAFH-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428–37.
- 24, , . A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115: 745–8.
- 25. About arithmetic formulas for calculating ideal body weight. http://www.halls.md/ideal-weight/devine.htm. Accessed 29 October 2005, 2 November 2007.
- 26National Center for Health Statistics. National Health and Nutrition Examination survey, CDC growth charts: United States. http://www.cdc.gov/growthcharts/. Accessed 31 January 2010.
- 27, , , , , , , , . Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298–302.
- 28, , , , , , , , , , , , , , , , , , , , the Recombinant Factor VIII Study Group. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800–5.
- 29, , . The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group. Semin Hematol 1991; 28: 29–35.
- 30, , . In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2–8.